Omeros Corporation (NASDAQ:OMER) was downgraded by research analysts at Cowen and Company from an “outperform” rating to a “market perform” rating in a research note issued on Thursday.

A number of other analysts have also recently weighed in on the stock. Maxim Group set a $24.00 target price on shares of Omeros Corporation and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Wedbush reiterated an “outperform” rating and set a $47.00 price target on shares of Omeros Corporation in a report on Friday, August 18th. Zacks Investment Research upgraded shares of Omeros Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $19.00 price target (up previously from $15.00) on shares of Omeros Corporation in a report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Omeros Corporation has an average rating of “Hold” and a consensus target price of $34.83.

Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.12. The business had revenue of $17.15 million during the quarter, compared to analyst estimates of $14.63 million. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. The firm’s quarterly revenue was up 71.5% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/02/omeros-corporation-omer-downgraded-by-cowen-and-company.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of OMER. Nwam LLC increased its holdings in shares of Omeros Corporation by 10.1% in the 3rd quarter. Nwam LLC now owns 46,520 shares of the biopharmaceutical company’s stock worth $1,006,000 after buying an additional 4,280 shares during the last quarter. Chicago Equity Partners LLC increased its holdings in shares of Omeros Corporation by 268.3% in the 3rd quarter. Chicago Equity Partners LLC now owns 195,875 shares of the biopharmaceutical company’s stock worth $4,235,000 after buying an additional 142,695 shares during the last quarter. Tocqueville Asset Management L.P. increased its holdings in shares of Omeros Corporation by 0.7% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 480,896 shares of the biopharmaceutical company’s stock worth $10,397,000 after buying an additional 3,430 shares during the last quarter. Ingalls & Snyder LLC increased its holdings in shares of Omeros Corporation by 0.3% in the 3rd quarter. Ingalls & Snyder LLC now owns 5,161,035 shares of the biopharmaceutical company’s stock worth $111,582,000 after buying an additional 17,746 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. bought a new position in shares of Omeros Corporation in the 2nd quarter worth $456,000. Institutional investors and hedge funds own 44.91% of the company’s stock.

About Omeros Corporation

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.